BioCentury
ARTICLE | Clinical News

T902611: TLRK will begin 2 Phase II trials in the U.S. and Europe this quarter. Each trial will include 60-70 patients.

April 22, 2002 7:00 AM UTC

Tularik Inc. (TLRK), South San Francisco, Calif. Product: T902611 (T611) Business: Infectious diseases Therapeutic category: Viral replication Target: CMV primase Description: Selective inhibitor of ...